Sugi Predict

Sugi Predict / Compounds / SCHEMBL13740320

SCHEMBL13740320

SCHEMBL13740320

O=C(NCC1CCN(C(=O)O)C1)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TPSAB1 Q15661 3/20 0.53
▸ TPSD1 Q9BZJ3 3/20 0.53
▸ TPSG1 Q9NRR2 3/20 0.53
▸ TGM2 P21980 2/20 0.52
▸ F13A1 P00488 1/20 0.52
▸ TGM1 P22735 1/20 0.52
▸ GRIN2B Q13224 5/20 0.51
▸ CYP2D6 P10635 3/20 0.50
▸ CYP2C9 P11712 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ CYP3A4 P08684 2/20 0.47
▸ CTSL P07711 1/20 0.47
▸ CTSB P07858 1/20 0.47
▸ CTSK P43235 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ F2 P00734 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13739493 1.00 TPSAB1 (0.53) TPSAB1TPSD1TPSG1TGM2F13A1
SCHEMBL13741073 1.00 TPSAB1 (0.53) TPSAB1TPSD1TPSG1TGM2F13A1
SCHEMBL2766871 0.93 PREP (0.50) TPSAB1TPSD1TPSG1TGM2F13A1
SCHEMBL27714000 0.93 PREP (0.50) TPSAB1TPSD1TPSG1TGM2F13A1
SCHEMBL1240612 0.92 TPSAB1 (0.58) TPSAB1TPSD1TPSG1TGM2F13A1
SCHEMBL1840977 0.90 LMNA (0.51) TPSAB1TPSD1TPSG1TGM2F13A1
SCHEMBL19123507 0.86 KEAP1 (0.55) TPSAB1TPSD1TPSG1TGM2F13A1
SCHEMBL29532829 0.86 GRIN2B (0.67) TPSAB1TPSD1TPSG1TGM2F13A1
SCHEMBL23522808 0.85 SMN1; SMN2 (0.47) TPSAB1TPSD1TPSG1GRIN2BCYP2D6
SCHEMBL12723099 0.85 KDM4E (0.60) TPSAB1TPSD1TPSG1GRIN2BCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3468970-A1 NEW ANTIBACTERIAL COMPOUNDS Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) 2019-04-17 — — EP disclosed
EP-3468975-A1 NEW ANTIBACTERIAL COMPOUNDS Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) 2019-04-17 — — EP disclosed
US-10064839-B2 Methods of treating liver diseases ZAFGEN, INC. (US) 2018-09-04 — — US disclosed
US-20180002307-A1 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. 2018-01-04 — — US disclosed
WO-2017211759-A1 NEW ANTIBACTERIAL COMPOUNDS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2017-12-14 — — WO disclosed
WO-2017211760-A1 NEW ANTIBACTERIAL COMPOUNDS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2017-12-14 — — WO disclosed
US-20170326099-A1 METHODS OF TREATING LIVER DISEASES ZAFGEN, INC. 2017-11-16 — — US disclosed
US-9617237-B2 Partially saturated tricyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2017-04-11 — — US disclosed
US-9561209-B2 Methods of treating liver diseases ZAFGEN, INC. (US) 2017-02-07 — — US disclosed
US-20170001973-A1 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. 2017-01-05 — — US disclosed
EP-2705030-B1 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-07-27 — — EP disclosed
US-9290472-B2 Partially saturated tricyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2016-03-22 — — US disclosed
US-20160058731-A1 METHODS OF TREATING LIVER DISEASES ZAFGEN, INC. (US) 2016-03-03 — — US disclosed
EP-2916833-A1 METHODS OF TREATING LIVER DISEASES Zafgen, Inc. (US) 2015-09-16 — — EP disclosed
WO-2014071368-A1 METHODS OF TREATING LIVER DISEASES ZAFGEN, INC. (US) 2014-05-08 — — WO disclosed
US-20140088078-A1 Partially Saturated Tricyclic Compounds and Methods of Making and Using Same ZAFGEN, INC. (US) 2014-03-27 — — US disclosed
WO-2012154676-A9 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC. (US) 2014-03-27 — — WO disclosed
EP-2705030-A1 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC. (US) 2014-03-12 — — EP disclosed
WO-2012154676-A1 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2012-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001973-A1 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME DNPEP, CES2, AADAC TPSAB1 286/4885TPSD1 268/4885TPSG1 273/4885
US-20170326099-A1 METHODS OF TREATING LIVER DISEASES ENPEP, GOT2, METAP2 TPSAB1 223/4885TPSD1 657/4885TPSG1 219/4885
US-10064839-B2 Methods of treating liver diseases ENPEP, GOT2, METAP2 TPSAB1 223/4885TPSD1 657/4885TPSG1 219/4885
US-20160058731-A1 METHODS OF TREATING LIVER DISEASES ENPEP, GOT2, METAP2 TPSAB1 223/4885TPSD1 657/4885TPSG1 219/4885
US-20180002307-A1 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME DNPEP, CES2, AADAC TPSAB1 286/4885TPSD1 268/4885TPSG1 273/4885
US-20140088078-A1 Partially Saturated Tricyclic Compounds and Methods of Making and Using Same DNPEP, CES2, AADAC TPSAB1 286/4885TPSD1 268/4885TPSG1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.